New Report on Major Depressive Disorder - Could Cymbalta (duloxetine) be at Risk of Being Seen as a Me-Too SNRI.DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/reports/c35651) has announced the addition of Major Depressive Disorder Major depressive disorder A mood disorder characterized by profound feelings of sadness or despair. Mentioned in: Conduct Disorder major depressive disorder - Duloxetine - Fulfilling An Unmet Need? to their offering. Major Depressive Disorder (MDD MDD Major depressive disorder, see there ) is estimated to affect over 34 million individuals yearly across the seven major markets. Only a fraction of this patient population is treated adequately, resulting in lost productivity, unnecessary patient suffering and unfulfilled revenue potential for manufacturers. Scope of this title: --Analysis of a survey of 180 prescribing physicians in the seven major markets as well as in-depth interviews with Key Opinion Leaders --Detailed treatment trees showing the prevalence, diagnosis and treatment rates of Major Depressive Disorder across the seven major markets --Discussion of the influence of treatment guidelines guidelines, n.pl a set of standards, criteria, or specifications to be used or followed in the performance of certain tasks. on physicians --Insight into diagnostic and therapeutic unmet needs, and recommendations to aid market penetration Noun 1. market penetration - the extent to which a product is recognized and bought by customers in a particular market penetration - the act of entering into or through something; "the penetration of upper management by women" and maximize prescription rates Highlights of this title: Individuals with milder forms of MDD are unlikely to present to physicians. Across the seven major markets, only around a half of individuals are then accurately diagnosed at first presentation. Despite safety concerns surrounding some of the newer antidepressants Antidepressants Medications prescribed to relieve major depression. Classes of antidepressants include selective serotonin reuptake inhibitors (fluoxetine/Prozac, sertraline/Zoloft), tricyclics (amitriptyline/ Elavil), MAOIs (phenelzine/Nardil), and heterocyclics , the prescribing habits of physicians have changed little, suggesting that the concerns may have been over-hyped. Cymbalta (duloxetine) is at risk of being seen as a me-too SNRI SNRI Serotonin and Norepinephrine Reuptake Inhibitor SNRI Sierra Nevada Research Institute (University of California - Merced) SNRI Stark Neurosciences Research Institute (Indiana University) . Our primary research suggests that by focusing on the treatment of painful physical symptoms of depression, Lilly might be missing the drugs more significant advantages. Reasons to order your copy: --Identify which healthcare professional is responsible for treating patients with differing severities of MDD, allowing for efficient product marketing --Ascertain the preferred and most frequently prescribed pre·scribe v. pre·scribed, pre·scrib·ing, pre·scribes v.tr. 1. To set down as a rule or guide; enjoin. See Synonyms at dictate. 2. To order the use of (a medicine or other treatment). drugs for first and second-line therapy, gaining key insight into the competitive landscape --Identify unmet needs to enhance development and market penetration strategies of MDD drugs Chapters are as follows:- Chapter 1 Executive summary Scope of the analysis Chapter 2 Introduction and scope Chapter 3 Country treatment trees Chapter 4 Epidemiology epidemiology, field of medicine concerned with the study of epidemics, outbreaks of disease that affect large numbers of people. Epidemiologists, using sophisticated statistical analyses, field investigations, and complex laboratory techniques, investigate the cause and patient segmentation of mdd Chapter 5 Presentation & referral Chapter 6 Diagnosis of mdd Chapter 7 Treatment guidelines Chapter 9 Prescribing trends Chapter 10 Factors influencing prescribing trends Chapter 11 Improving treatment outcomes APPENDIX A APPENDIX B APPENDIX C For more information visit http://www.researchandmarkets.com/reports/c35651 Source: Datamonitor |
|
Printer friendly
Cite/link
Email
Feedback
Reader Opinion